...
首页> 外文期刊>Leukemia >Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy
【24h】

Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy

机译:来自B慢性淋巴细胞性白血病(B-CLL)患者的自然杀手(NK)和自然杀手样T(NKT)细胞群体的扩大:细胞免疫疗法的潜在来源

获取原文
           

摘要

B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the Western world. It is currently an incurable disease, making new treatment options such as immunotherapy desirable. Monoclonal antibodies (Mabs) to surface antigens of the tumor cell is one option. Administration of cytotoxic cells such as natural killer (NK) and natural killer-like T (NKT) cells expanded in vitro might be a useful treatment modality alone or in combination with MAbs. A limiting step in the development of successful cellular immunotherapy has been the availability of appropriate cytotoxic cells. Here, we report the feasibility of expanding populations of the human killer cells, CD3-CD56+ NK and CD3+CD56+ NKT cells, from peripheral blood mononuclear cells (PBMCs) of B-CLL patients. The influence of tumor B cells on the in vitro expansion of killer cells was assessed by depleting B cells from PBMCs by microbead separation before culture. The 21-day cultures from both B-cell- and non-B-cell-depleted PBMC showed a marked expansion of NK cells, and also of T cells, among which almost half had the NKT phenotype. Depletion of B cells before culture did not change the expansion rates of NK and NKT cells significantly. In patients with progressive B-CLL, NK cell expansion capacity was improved after fludarabine treatment when compared to samples obtained before treatment. Repeated samples of PBMCs from individual untreated patients with both indolent and progressive disease cultured under identical conditions gave similar NK cell expansion rates. Expanded killer cell populations had cytotoxic function against the NK-sensitive target K562 cell line and expressed high levels of Granzyme B. From our studies, we conclude that NK cells as well as NKT cells from the peripheral blood of B-CLL patients can be expanded, and that these cells have cytotoxic capacity.
机译:B细胞慢性淋巴细胞性白血病(B-CLL)是西方世界最常见的白血病。它是目前无法治愈的疾病,因此需要新的治疗方法,例如免疫疗法。一种针对肿瘤细胞表面抗原的单克隆抗体(Mabs)是一种选择。施用体外扩增的细胞毒性细胞(例如自然杀伤(NK)和自然杀伤样T(NKT)细胞)可能是单独使用或与单克隆抗体联合使用的一种有用治疗方式。成功的细胞免疫疗法发展的一个限制步骤是适当的细胞毒性细胞的可用性。在这里,我们报告了从B-CLL患者的外周血单核细胞(PBMC)扩大人类杀伤细胞CD3-CD56 + NK和CD3 + CD56 + NKT细胞种群的可行性。通过在培养前通过微珠分离从PBMC中消耗B细胞来评估肿瘤B细胞对杀伤细胞体外扩增的影响。来自B细胞贫化和非B细胞贫化的PBMC的21天培养物显示NK细胞以及T细胞的显着扩增,其中几乎一半具有NKT表型。培养前B细胞的耗竭并没有明显改变NK和NKT细胞的扩增速率。在进行性B-CLL患者中,与治疗前获得的样品相比,氟达拉滨治疗后NK细胞的扩增能力得到了改善。来自在相同条件下培养的患有惰性和进行性疾病的未治疗个体患者的PBMC的重复样品给出了相似的NK细胞扩增速率。扩大的杀伤细胞群对NK敏感的靶K562细胞系具有细胞毒功能,并表达高水平的颗粒酶B。根据我们的研究,我们得出结论,可以扩增B-CLL患者外周血的NK细胞和NKT细胞,并且这些细胞具有细胞毒性能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号